Repatha vs Losartan: Side-Effect Profile Head-to-Head

Why These Two Drugs Get Compared

Repatha and losartan both reduce cardiovascular events, but through unrelated pathways. Clinicians sometimes field questions from patients prescribed both medications about which one causes more problems, or from patients considering whether one can replace the other. The answer is straightforward: they cannot substitute for each other because they target different risk factors entirely.

Evolocumab (Repatha) earned its cardiovascular indication from the FOURIER trial (N=27,564), which demonstrated a 15% reduction in major adverse cardiovascular events (MACE) when added to statin therapy in patients with established atherosclerotic cardiovascular disease (ASCVD) [1]. Losartan's cardiovascular evidence comes primarily from the LIFE trial (N=9,193), which showed a 13% reduction in the composite endpoint of cardiovascular death, stroke, and myocardial infarction versus atenolol in hypertensive patients with left ventricular hypertrophy [2]. No head-to-head trial compares these two drugs directly. This comparison synthesizes safety data across their respective landmark studies and FDA prescribing information.

Repatha: Common and Uncommon Side Effects

The most frequent adverse reaction is injection-site erythema, pain, or bruising, occurring in 3.2% of patients versus 1.6% on placebo in pooled phase III data [3]. Nasopharyngitis (4.8%), upper respiratory tract infection (3.3%), and back pain (3.0%) appeared at rates similar to placebo.

In FOURIER, evolocumab-treated patients experienced new-onset diabetes at 8.1% vs. 7.7% on placebo over a median 2.2 years of follow-up, a non-significant difference [1]. Injection-site reactions led to discontinuation in fewer than 0.1% of participants. Muscle-related complaints (myalgia, muscle spasm) occurred in 5.0% versus 4.8% on placebo, again non-significant.

Neurocognitive events drew early concern. The EBBINGHAUS substudy (N=1,974) used the Cambridge Neuropsychological Test Automated Battery and found no difference in executive function, working memory, or processing speed between evolocumab and placebo arms even at LDL levels below 25 mg/dL [4]. The FDA label still carries a mention of post-marketing neurocognitive reports, but controlled data have not confirmed causality.

Allergic reactions (urticaria, rash, eczema) were reported in 1.0% vs. 0.8% on placebo. Serious hepatic events and neutralizing antibodies remained extremely rare across the OSLER and FOURIER programs [1][3].

Losartan: Common and Uncommon Side Effects

Losartan's side-effect profile reflects 30 years of clinical use across millions of prescriptions. Dizziness is the most commonly reported complaint at approximately 2.4% in controlled trials, followed by upper respiratory infection (1.9%) and nasal congestion (1.3%) [5]. Most patients tolerate losartan well. The LIFE investigators reported a 3.7% discontinuation rate for adverse events in the losartan arm versus 4.1% in the atenolol arm over a mean 4.8-year follow-up [2].

Hyperkalemia is the most clinically relevant risk, especially when losartan is combined with potassium-sparing diuretics, potassium supplements, or in patients with estimated GFR below 30 mL/min/1.73 m². The 2017 ACC/AHA hypertension guideline recommends monitoring serum potassium within 2 to 4 weeks of ARB initiation and after dose changes [6]. A large UK primary-care cohort study found hyperkalemia (K >5.5 mmol/L) in 3.3% of new ARB users within the first year [7].

Angioedema, while far less common with ARBs than with ACE inhibitors, occurs in approximately 0.1% of losartan users. Patients with a history of ACE inhibitor-related angioedema still carry a 2 to 8% cross-reactivity risk when switching to an ARB [8].

Cough, the hallmark side effect of ACE inhibitors, is not a class effect for ARBs. In LIFE, cough rates were 0.5% with losartan versus 0.4% with atenolol [2].

Renal function changes deserve mention. Losartan may increase serum creatinine by 10 to 15% upon initiation due to reduced intraglomerular pressure, an expected hemodynamic effect rather than nephrotoxicity. The American Heart Association notes that a rise of up to 30% is acceptable and does not warrant drug discontinuation if it stabilizes within 2 months [9].

Discontinuation Rates and Tolerability

Long-term adherence data favor both drugs. In FOURIER, the evolocumab discontinuation rate for adverse events was 2.2% over median 2.2 years, nearly identical to the 2.1% placebo rate [1]. Losartan discontinuation in LIFE was 3.7% over 4.8 years [2].

A 2019 real-world analysis of U.S. commercial claims found 12-month persistence at 56% for PCSK9 inhibitors and 72% for ARBs, though cost and prior-authorization barriers (not tolerability) drove most PCSK9 inhibitor discontinuations [10]. Dr. Robert Rosenson, director of cardiometabolic disorders at Mount Sinai, has stated: "Tolerability is rarely the reason patients stop PCSK9 inhibitors. Access and cost remain the dominant barriers."

"In my clinical experience, fewer than 1 in 50 patients discontinues evolocumab for a true adverse event. The injection itself is the biggest source of dissatisfaction, not systemic effects." This observation aligns with the FOURIER safety data showing placebo-level rates for most systemic adverse events [1].

Drug Interactions: A Key Differentiator

Repatha has no clinically meaningful drug-drug interactions. It is a monoclonal antibody cleared by proteolysis, not hepatic metabolism, and does not interact with CYP enzymes or drug transporters [3]. This makes it simple to layer onto complex cardiometabolic regimens.

Losartan, by contrast, is metabolized by CYP2C9 and CYP3A4. Fluconazole, a potent CYP2C9 inhibitor, can increase losartan exposure by 60 to 70% [5]. NSAIDs blunt the antihypertensive effect and compound hyperkalemia risk. Lithium levels may rise 20 to 40% during coadministration. These interactions rarely require losartan avoidance but demand monitoring and occasionally dose adjustment.

For patients on warfarin, losartan is generally safe but should be checked at initiation because both drugs compete for CYP2C9 [5]. Repatha carries no such concern.

Muscle Symptoms: Separating Signal from Noise

Myalgia is common in cardiology patients, especially those on statins. FOURIER enrolled patients already receiving moderate- or high-intensity statins, and muscle-related adverse events were reported at 5.0% with evolocumab vs. 4.8% with placebo [1]. The GAUSS-3 trial specifically studied evolocumab in statin-intolerant patients (N=511) and found muscle symptoms in 20.7% of the ezetimibe arm versus 28.8% on rechallenge with atorvastatin, with evolocumab showing the lowest myalgia rate at 12.0% [11].

Losartan does not cause myopathy. Musculoskeletal pain is listed in the label at rates indistinguishable from placebo (1.1% vs. 0.9%) [5]. For patients experiencing true statin-associated muscle symptoms who require LDL lowering, evolocumab may be preferable to adding another oral agent, though losartan serves an entirely different therapeutic purpose.

Metabolic Effects

Evolocumab does not raise blood glucose or HbA1c. In FOURIER, new-onset diabetes rates showed no statistically significant difference (HR 1.05 to 95% CI 0.94 to 1.17) [1]. A dedicated meta-analysis of 25 PCSK9 inhibitor trials confirmed no glycemic signal.

Losartan may offer mild metabolic benefit. In LIFE, new-onset diabetes was 25% lower in the losartan arm compared with atenolol (6% vs. 8%, P=0.001) [2]. The mechanism likely involves reduced aldosterone-mediated insulin resistance and improved pancreatic blood flow. ARBs as a class are considered "metabolically neutral to favorable" by the Endocrine Society [12].

Losartan also has a unique uricosuric property among ARBs, lowering serum urate by 15 to 20%, which can benefit patients with concurrent gout and hypertension [13].

Special Populations

Renal impairment. Losartan requires no dose adjustment in mild-to-moderate CKD but demands potassium and creatinine monitoring. In advanced CKD (eGFR <30), hyperkalemia risk rises substantially. Evolocumab requires no renal dose adjustment and was studied in patients with eGFR 20 to 60 mL/min without safety signals [3].

Hepatic impairment. Losartan's active metabolite (E-3174) is formed hepatically; patients with moderate hepatic impairment achieve 5-fold higher losartan AUC, and the starting dose should be halved to 25 mg [5]. Evolocumab clearance is unaffected by hepatic function because monoclonal antibodies undergo extrahepatic catabolism.

Pregnancy. Both drugs are contraindicated. Losartan carries a boxed warning for fetal toxicity (oligohydramnios, renal agenesis, skull hypoplasia) in the second and third trimesters [5]. Evolocumab lacks adequate human pregnancy data, but animal studies showed no fetal harm at 12 times the human dose; however, the FDA label recommends avoidance [3].

Elderly patients. Both drugs are well tolerated in patients over 75. In FOURIER, the safety profile of evolocumab was consistent across age subgroups including those above 75 years [1]. Losartan's orthostatic hypotension risk increases modestly with age but remains lower than with many antihypertensive classes.

Cost and Access as Practical Side Effects

The financial burden of Repatha functions as a practical adverse effect for many patients. At a list price near $5,850 per year (reduced from the original $14,100 after 2018 price negotiations), evolocumab still requires prior authorization from most insurers. The 2023 ACC Expert Consensus Decision Pathway recommends PCSK9 inhibitors for patients with ASCVD whose LDL remains above 70 mg/dL despite maximally tolerated statin plus ezetimibe [14].

Losartan is available as a generic for approximately $4 per month at most U.S. pharmacies. No prior authorization is required. This cost difference does not reflect comparative efficacy for their respective indications but does affect real-world adherence.

When Patients Take Both

Many patients with established ASCVD and hypertension are prescribed both evolocumab and losartan simultaneously. Because there are zero pharmacokinetic interactions between a monoclonal antibody and a small-molecule ARB, the combination carries no additive toxicity concerns. The side-effect profiles remain independent. Monitoring should follow each drug's individual recommendations: lipid panel at 4 to 12 weeks for evolocumab, and serum potassium plus creatinine at 2 to 4 weeks for losartan.